Abstract
The omega 3 has a known anti-inflammatory effect which can be beneficial in many human diseases in the
respiratory & other systems.
In respiratory system its role is not mature yet as in asthma, COPD & bronchiectasis & most are still under study.
The safety issues also need to be addressed in the treatment with a relatively need medication.
To evaluate the use of omega-3 EPA/DHA oral softgel in the treatment of stable (not in exacerbation)
bronchiectasis regarding safety/efficacy effect.
44 Patients with stable bronchiectasis are randomly assigned to the active group (participants recei ve omega-3
EPA/DHA oral softgel (EPA 180mg &DHA 120mg ) once daily for 6 months in addition to their usual treatment)
or the control group (participants receive the usual treatment only for 4 months) from January 2013 to march
2016.
Inter ventional randomized parallel assignment study concern in the safet y /efficacy of a suggested treatment.
Omega 3 can used in patients with stable bronchiectasis with the expected benefits:
1- reduce exacerbation rate
2- improve FEV1
3- may improve CAT scoreThe treatment does not cause serious side effects r egarding the safety aspect apart from
the fishy odor sensed by the patients .